The stack KLOW was developed by the vendor and stands for a mixture of 4 peptides marketed as a research chemical. The four parts include BPC-157, TB-500 (Thymosin Beta-4 fragment), GHK-Cu (a tripeptide that binds copper) and KPV (the C-terminal part of alpha-MSH). All 4 peptides did not receive FDA approval. There was no study on the combination of 4 peptides that was published in either human or rodent trials. Each peptide has its research background and reasons why they can be combined.
The standard vendor ratio consists of 10 mg BPC-157, 10 mg TB-500, 50 mg GHK-Cu, and 10 mg KPV in a single 80 mg vial. The US Peptide Labs store page does not provide the details of each peptide's weight in the mixture, so ensure that you double-check the ratio based on your lot before making dose calculations. For $145.00, you will get 10 mL of lyophilized powder processed in US labs. You can also get free shipping for orders over $70 and get the COA from an independent laboratory.
| Component | Class | Primary Research Focus | Evidence Level |
|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide. | Measurement of gut integrity, regeneration of tendons and ligaments, tissue healing. | In vivo, on animal models. |
| TB-500 | Peptide fragment with actin-binding properties. | Recovery, muscle regeneration, wound healing, angiogenesis. | In rodents and in vitro. |
| ##LINK_1## | Copper tripeptide. | Producción de colágeno, remodelación de la piel, señales del folículo piloso. | Estudios tópicos en roedores y humanos. |
| KPV | Alpha-MSH E-fragment. | Anti-inflammatory signalling, protection of gut mucosa. | Rodent, oral colitis models, in vitro. |
Every benefit mentioned in this report comes from the effect caused by the individual peptide that contributed to the effect. Interpretation of combined effects is speculative.
BPC-157 is the most investigated element in the mixture for tissue recovery. Experiments on rodents have confirmed that the substance speeds up the process of healing various tissues like gastric ulcers, tendon-bone connections, and intestinal anastomoses. What happens is that the synthesis of local growth hormones is activated and nitric oxide path has been modified.
TB-500 acts in a systemic way rather than locally. This peptide is a fragment of Thymosin Beta-4 and is known for the ability to promote actin polymerization which is essential in cell migration during wound healing. Evidence from rodent studies has suggested that TB-500 also has a role in the recovery of cardiac and skeletal muscles after injury. Systemic action is the main distinction from BPC-157 in the context of stacking them.
GHK-Cu has the largest amount of human-related evidence available. Studies in humans using topical formulations on the skin demonstrate improved synthesis of both collagen and glycosaminoglycans. Copper ions also affect the activity of lysyl oxidase, which in turn is responsible for forming cross-links between collagen strands. Thus, GHK-Cu is the most researched of the four choices.
KPV is the peptide that provides a clear distinction between KLOW and the GLOW compounds. In oral colitis rodent studies, KPV inhibited cytokine production and inflammation in the gut through melanocortin receptor sites. To date, there is no information in the literature on the possible effects of KPV on liver or proliferative factors, which is worth noting due to the discussions regarding angiogenesis that arise concerning BPC-157 and TB-500. More detailed information can be found in the full KPV peptide profile.
| Syringe | Draw Volume (mL) | BPC-157 (mcg) | TB-500 (mcg) | GHK-Cu (mcg) | KPV (mcg) | Total Blend (mg) |
|---|---|---|---|---|---|---|
| 10 units | 0.10 mL. | 50 mcg. | 50 mcg. | 250 mcg. | 50 mcg. | 0.40 mg. |
| 15 units | 0.15 mL. | 75 mcg. | 75 mcg. | 375 mcg. | 75 mcg. | 0.60 mg. |
| 20 units | 0.20 mL. | 100 mcg. | 100 mcg. | 500 mcg. | 100 mcg. | 0.80 mg. |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
Published rodent studies on this type of peptide blend tend to land in the <span style="color: #8B6F47; font-weight: 500;">10 to 20 units per day</span> range via subcutaneous administration. Draw 20 units from a 2 mL reconstitution and you deliver 100 mcg each of BPC-157, TB-500 and KPV, plus 500 mcg of GHK-Cu. Research cycle duration in the literature runs 6 to 12 weeks, on either a 5-days-on / 2-days-off or a 7-days-on schedule depending on the protocol.
</p>
Get US Peptides dosage calculator provides a guide containing instructions for reconstitution and conversion from units to volumes. The page for KLOW-specific dosing at the link getuspeptides.com/peptide-dosage/klow/ has all relevant protocol tables included.
Reconstitution utilizes between two and three milliliters of bacteriostatic water for every vial. This means there is less concentration to draw from, which also damages the GHK-Cu concentration at the injection site and lowers the level of stinging. This question gets asked by researchers all the time: "why is the KLOW stingier than the BPC-157 by itself?" The answer is GHK-Cu. Just dilute more.
After you have mixed the ingredients, place them in the refrigerator at temperatures between 2 and 8 degrees Celcius and consume it within a time duration of approximately four weeks. Store the lyophilized powder in cold, dry, and dark places before it gets reconstituted.
Protocols for research purposes indicate the need for subcutaneous injections in the abdominal region changing injection sites to minimize focal discomfort. If a study focuses on a certain tissue (tendon within the tendon tissue or tract in the gastro intestinal region), then some research procedures require injecting specific region rather than using central installation. In most cases, protocols require performing injections in the morning or using its division in morning and night in relation to one day dose. There are no any human pharmacokinetic studies indicating that different outcomes based on injections time in relation to each component of the mix are possible.
The components are common across all three stacks, yet the differences are slight but significant relative to the research inquiry.
| Stack | Components | Primary Research Angle | What It Lacks vs KLOW |
|---|---|---|---|
| KLOW | BPC-157 + TB-500 + GHK-Cu + KPV. | Recovery and tissue repair, wide anti-inflammatory properties, gut health. | Full reference stack. |
| GLOW | BPC-157 + TB-500 + GHK-Cu. | Healing and recovery, repair, collagen and skin. | No KPV - no melanocortin role in healing or gut mucosal action. |
| Wolverine | BPC-157 + TB-500. | Recovery from injuries and total repair. | No GHK-Cu, no KPV - no collagen or anti-inflammatory peptide. |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
KLOW is GLOW plus KPV. That one change opens an entirely new research angle: gut mucosal inflammation models and systemic anti-inflammatory effects. If the study is purely about musculoskeletal recovery with no gut or inflammatory component, the <a href="https://uspeptidelabs.co/products/bpc-157-tb-500" style="color: #8B6F47; font-weight: 500;">Wolverine stack (BPC-157 / TB-500) at $85.00</a> is the more economical option. If the focus is collagen and skin remodeling without KPV or anti-inflammatory properties, <a href="https://uspeptidelabs.co/products/ghk-cu" style="color: #8B6F47; font-weight: 500;">GHK-Cu single peptide at $60.00</a> gives a cleaner isolated variable.
KLOW at $145.00 is the logical choice when all four mechanisms need to run at once, or when the researcher does not want the hassle of sourcing and combining four separate vials. The price per mcg of GHK-Cu inside KLOW is reasonable thanks to the 50 mg dose compared to buying an individual GHK-Cu vial, but the trade-off is that doses of the individual peptides cannot be adjusted separately.
</p>
According to KLOW, side effects have been reported that are specific to the components thereof. The term "adverse events" is not applied in the KLOW study with specific regard to a four-peptide combination.
GHK-Cu: Injection-site stinging and transient redness are the two complaints that are most often reported. More dilution during reconstitution decreases both. The copper ion is responsible for the sting; it is not an allergic reaction in most cases but a local pH and ionic effect.
With regards to BPC-157, animal research findings suggest that these agents are well tolerated in rodents. Catastrophic nausea and sleepiness appears to be evident in anecdotal evidence. Questions still remain about the ability of BPC-157 to stimulate blood vessel growth in various tissues, despite its various uses having been documented in studies.
TB-500: The most common adverse effects reported include water retention and slight tiredness among rodents and in anecdotal observations. The same warning about angiogenesis applies here, as the long-term studies do not exist regarding the matter.
KPV: The KPV literature does not show any evidence of liver toxicity or any signs of proliferation. Some studies in mice show that KPV reduces hunger slightly via modulation of melanocortin receptors.
There is something that I have identified in query made by researchers using KLOW for the first time. Researchers assume that all discomfort emanating from the injection site results from BPC-157 because they are aware of this peptide only. In present case, the GHK-Cu is in fact the source of the problem. If the volume of reconstitution is switched from 2 mL to 3 mL, then the pain diminishes without affecting the dosage if the drawing is corrected.
None of KLOW's four peptides have passed the FDA for any thinking regarding any part of its drug. In September 2023, BPC-157 was placed into FDA Category 2 of the 503A bulk drug substances list. This means BPC-157 cannot be utilized by compounding pharmacies under 503A. As a single listing, this has the effect of prohibiting any type of KLOW blend formulation through the 503A compounding pathway. TB-500, GHK-Cu and KPV do not have any other 503A restrictions as of mid-2023.
US Peptide Labs is a chemical supplier and does not operate as a pharmacy under the regulations of 503A or 503B. KLOW can be obtained only as a material intended for laboratory research by researchers over the age of 21. It is not supplied for consumption by any human beings, and no recommendation or instructions of use accompany the substance. The customers are encouraged to check the information available at COA documentation and Get US Peptides COA reading guide.
TB-500 is clearly mentioned on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), being banned in and out of sport. As TB-500 is one of the components of KLOW, the whole KLOW mixture is banned for every athlete who participates in WADA-governed events. There's no ambiguity here. Any researcher who is a competitive athlete in the sport with tests deserves to know this prior to working with TB-500.
At present, the name of BPC-157 does not appear on the WADA list. However, due to the use of terms like "related substances" it may still be interpreted differently in the future. GHK-Cu and KPV are also absent from the current list.
The dosage chart is described in numerical terms in this paragraph. Here we examine the various hypotheses on which the methods discussed in literature regarding the preparation of BPC-157 and TB-500 are based.
Cycling: The typical cycle length for each substance, BPC-157 and TB-500, is 6-8 weeks. No research exists on the cycles for the four-peptide combination. Commonly, a 5 on / 2 off cycling is used in rodent studies, though some protocols describe daily administrations. Dosage: the frequency can be once a day in the morning or divided between two dosages—morning and evening.
The combination protocols page from Get US Peptides discusses the method that scientists utilize to create multi-peptide cycles along with washout considerations. The peptides for healing research hub delves into the more general context of its position among the other recovery-oriented substances.
The research queries concerning the four-peptides mixture, KLOW, can be categorized in several ways. The table provided here is a useful guide, and not an advice for treatment.
The commonality of BPC-157 with KPV with respect to the gut is one of the more intriguing facets of the KLOW formulation on a research and design aspect. Both act on gut mucosal tissues but they do so in different ways: BPC-157 does so through modulation of growth hormone receptors and nitric oxide, while KPV uses melanocortin receptor pathways. Their influence (if they have any) is one that has not yet been explored.
The US Peptide Labs catalog offers KLOW exclusively at uspeptidelabs.co/products/bpc-ghk-tb-kpv. The cost of a single vial is $145. There are reductions in price for orders in bulk- $137.75 each for 2+ units and $130.50 each for 5+ units. Orders over $70 are eligible for free shipping within the US. The products are sent from a US site with a tracking number.
All lots feature a developed lot number on the bottom of the vial. We can supply our independent third-party COA testing upon request through our shop. Researchers must validate the existing purity documents before they start their experiments; the entire COA process related to peptide research materials can be found at the mentioned link .
You can find the complete KLOW composition profile, including mechanism notes and literature citations on each element, at getuspeptides.com/peptide-library/klow/ . Each single element profile can be accessed from that hub. The healing and recovery collection web page at US Peptide Labs contains the Wolverine stack as well as GHK-Cu, BPC-157 and TB-500 among the KLOW options for those researchers who prefer to compare alternatives or use the components separately.
The domestic synthesis by means of domestic cold-chain transport is more time-efficient and less temperature-dependent than acquisition of materials from overseas, which plays a big role in peptide preservation.
In research circles, KLOW has been examined for its coverage in gut membrane repair (BPC-157, KPV), whole tissue repair (TB-500), andcollagen tissue regeneration (GHK-Cu) along the lines of its four components. Nevertheless, the combination has never been used in any published study. The research record of every single element has been summarized in the table presented above.
Typically, research protocols quote amounts of 10 to 20 units per day via subcutaneous route. For example, for reconstituting an 80 mg vial at a 2 ml volume using standard ratio of 10:10:50:10 mg the volume that gives 20 units would provide 100 mcg each of BPC-157, TB-500 and KPV and 500 mcg GHK-Cu. Make sure to check the ratio of your batch before proceeding with calculations.
The formula for KLOW is GLOW with the addition of KPV. The GLOW formula is made up of BPC-157, TB-500 and GHK-Cu. KPV has been added to KLOW as the mucosal and melanocortin receptor anti-inflammatory component. Researchers with experiments aimed at systemic anti-inflammatory and gut inflammation would prefer KLOW over GLOW. On the other hand, researchers who are only interested in musculoskeletal healing and collagen synthesis might not require KPV. The GLOW peptide profile goes into depth about three-peptide blend.
Human safety data for the four-peptide combination is not available. However, individual component data indicate that GHK-Cu results in stinging at the injection site, the degree of which is affected by dilution. Furthermore, TB-500 has been linked to mild fatigue and some water retention in certain incidences, and BPC-157 and TB-500 are still in question due to concerns related to angiogenesis from the rodent literature. Lastly, KPV is reported to show no evidence of liver toxicity or signs of proliferation in studies.
None of the four peptides found in KLOW have received approval from the FDA. In September 2023, BPC-157 was classified as Category 2 on the FDA 503A bulk drug substances list, which means that it cannot be used in any type of compounded preparations. KLOW is marketed as a product only intended for research purposes.
US Peptide Labs is associated with this website. The product is manufactured in the United States and shipped by courier with tracking to locations inside the US and it costs $70. The price is $145.00 for one vial, $137.75 for two or more, and $130.50 for five and more. Sales are open only to buyers who are 21 years old or older.